The new approval is for patients with germline BRCA-mutated, HER2 negative locally advanced or metastatic breast cancer.
International Approvals
Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer
The new approval is for patients with germline BRCA-mutated, HER2 negative locally advanced or metastatic breast cancer.
International Approvals
